Sweden · Delayed Price · Currency is SEK Cantargia AB Earnings Call Transcripts
Fiscal Year 2025
-
Advanced nadunolimab to pivotal trial readiness in PDAC, reported strong financials with first-ever annual profit, and secured a robust cash runway into 2028. Investor interest in PDAC is rising, and key milestones are targeted for 2026.
-
Q3 2025 saw a major financial boost from the Otsuka deal, resulting in first-ever reported profits and a strengthened cash position. Nadunolimab in PDAC remains the strategic focus, with a pivotal trial planned for mid-2026, while new pipeline assets advance in preclinical stages.
-
Nadunolimab, a pivotal-ready antibody for PDAC, showed improved survival in patients with high IL1RAP levels and received FDA fast-track status. Financial flexibility from a major partnership supports further development, with a pivotal trial and biomarker-driven strategy planned.
-
Nadunolimab advances as a lead IL-1RAP antibody in cancer, with FDA fast-track status and a focus on high IL-1RAP patients. A major Otsuka deal provides financial flexibility, while ongoing trials and a new CEO's strategic focus aim to maximize the asset's potential.
-
Otsuka acquired CAN10 for $33M upfront plus up to $580M in milestones, with deal closing in Q3 2025. Operating expenses fell 10% year-over-year, and a new CEO, Dr. Hilde Steineger, was appointed. Nadunolimab received FDA fast-track in PDAC, and the company expects improved financial stability.
-
Strong clinical progress with CANTEN and nadunolimab, including phase 1 completion and new indications, drove higher R&D costs and operating losses. Cash runway extends into Q4 2025, but additional funding is needed amid challenging biotech market conditions.
Fiscal Year 2024
-
Leadership transition brings focus on value creation and transactions for lead assets. Operating expenses fell 42% year-over-year, with a strengthened cash position post-rights issue. Multiple clinical milestones and potential partnerships are expected in 2024–2025.
-
Progress in both oncology and immunology programs, with strong clinical data and FDA clearance for a leukemia study. Lower R&D and G&A expenses led to a SEK 122 million YTD loss; a rights issue aims to extend the cash runway to mid-2026 and fund key milestones.
-
Two clinical programs advanced with strong safety and efficacy signals; operating expenses reduced 39% year-over-year. Financing remains a key focus, with available funds expected to last into 2025 and major trials contingent on securing additional capital.